8-K: Nuvalent Reports Positive Pivotal Data for Zidesamtinib in Advanced ROS1-Positive Lung Cancer, Accelerates Regulatory Path

Nuvalent, Inc. announced positive pivotal data for its ROS1-selective inhibitor, zidesamtinib, in pre-treated advanced ROS1-positive non-small cell lung cancer patients, and outlined progress on its front-line development strategies for zidesamtinib and neladalkib.

Summary

• Nuvalent, Inc. announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) from the global ARROS-1 Phase 1/2 clinical trial.
• The company reported preliminary data from the Phase 2 TKI-naive cohort in its ARROS-1 clinical trial, with global enrollment ongoing.
• Nuvalent is advancing clinical startup activities to support the global initiation of the ALKAZAR Phase 3, randomized, controlled trial, designed to evaluate neladalkib, a novel ALK-selective inhibitor, versus alectinib for TKI-naive ALK-positive NSCLC, with enrollment expected to begin early in the second half of 2025.
• Nuvalent completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) and aligned on plans for an NDA submission for zidesamtinib for TKI pre-treated patients with locally advanced or metastatic ROS1-positive NSCLC.
• The FDA agreed to accept the NDA for participation in the Real-Time Oncology Review (RTOR) pilot program, which facilitates earlier submission of topline data.
• The company plans to initiate a rolling NDA submission in July 2025, with completion targeted for the third quarter of 2025, and continues to engage with the FDA on potential opportunities for line-agnostic expansion.
• In the pivotal dataset for TKI pre-treated ROS1-positive NSCLC (n=117), the objective response rate (ORR) was 44% (95% CI: 34, 53) by blinded independent central review (BICR).
• The emerging median duration of response (mDOR) for responders was 22.0 months (95% CI: 17.2, NE) overall, with durability of response estimated at 84% at 6 months, 78% at 12 months, and 62% at 18 months.
• In patients with a secondary ROS1 resistance mutation (G2032R, n=26), the ORR was 54% (95% CI: 33, 73).
• For patients with measurable CNS lesions by BICR at baseline (n=56), the intracranial ORR (IC-ORR) was 48% with 20% (11/56) intracranial complete responses (CR), and IC-DOR at 12 months of 71% (95% CI: 46, 87).
• Zidesamtinib demonstrated a well-tolerated safety profile in 432 patients treated at the recommended phase 2 dose (RP2D); the most frequent treatment-emergent adverse events (TEAEs) occurring in ≥15% of patients were peripheral edema (36%), constipation (17%), blood CPK increase (16%), fatigue (16%), and dyspnea (15%).
• Dose reductions due to TEAEs occurred in 10% of patients, and 2% of patients discontinued treatment due to TEAEs.
• Preliminary data for 35 TKI-naive patients with advanced ROS1-positive NSCLC showed a preliminary ORR of 89% (31/35) and IC-ORR of 83% (5/6) in 6 patients with measurable intracranial lesions.

Sentiment

Score: 9

Explanation: The document reports highly positive clinical trial data for zidesamtinib, indicating strong efficacy and a well-tolerated safety profile across challenging patient populations, including those with resistance mutations and CNS metastases. The preliminary data for TKI-naive patients is also very encouraging. Furthermore, the FDA's acceptance into the RTOR program and the planned NDA submission signal significant progress towards commercialization. The advancement of the ALKAZAR Phase 3 trial for neladalkib also adds to the positive outlook.

Positives

• Positive pivotal data for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC, demonstrating an objective response rate (ORR) of 44% (n=117).
• Strong emerging median duration of response (mDOR) of 22.0 months in TKI pre-treated responders, indicating durable efficacy.
• Significant activity observed in patients with secondary ROS1 resistance mutation G2032R, with an ORR of 54% (n=26).
• High intracranial ORR (IC-ORR) of 48% in patients with measurable CNS lesions, including 20% intracranial complete responses, addressing a critical unmet need.
• Exceptional IC-ORR of 85% with 54% intracranial CRs in patients previously treated with crizotinib only, highlighting strong brain penetrance.
• Well-tolerated safety profile for zidesamtinib, consistent with its ROS1-selective, TRK-sparing design, with low rates of dose reductions (10%) and discontinuations (2%) due to TEAEs.
• Encouraging preliminary ORR of 89% in TKI-naive patients (n=35), suggesting strong potential for front-line use.
• FDA agreed to accept the NDA for zidesamtinib for participation in the Real-Time Oncology Review (RTOR) pilot program, potentially accelerating the review and approval process.
• Advancement of clinical startup activities for the ALKAZAR Phase 3 trial for neladalkib, indicating progress in the ALK-positive NSCLC program.

Risks

• Risks that the Company may not fully enroll its clinical trials or that enrollment will take longer than expected.
• Unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials.
• The risk that preliminary results of clinical trials may not be predictive of future results from the same or other trials.
• The risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.
• The risk that data from clinical trials may not be sufficient to support registration and that the Company may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib and neladalkib.
• The occurrence of adverse safety events.
• Risks that the FDA may not approve the Company's potential products on the timelines the Company expects, or at all.
• Risks of unexpected costs, delays, or other unexpected hurdles.
• Risks that the Company may not be able to nominate drug candidates from its discovery programs.
• The direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of the Company's clinical trials, strategy, and future operations, including the ARROS-1 trial and the ALKAZAR trial.
• The timing and outcome of the Company's planned interactions with regulatory authorities.
• Risks related to obtaining, maintaining, and protecting the Company's intellectual property.

Future Outlook

Nuvalent expects to begin enrollment for the ALKAZAR Phase 3 trial early in the second half of 2025. The company plans to initiate a rolling NDA submission for zidesamtinib in July 2025, targeting completion in the third quarter of 2025, and continues to engage with the FDA on potential opportunities for line-agnostic expansion.

Management Comments

• Nuvalent, Inc. announced positive pivotal data for zidesamtinib in TKI pre-treated patients with advanced ROS1-positive NSCLC from the global ARROS-1 Phase 1/2 clinical trial.
• Nuvalent announced progress on the front-line development strategies for its parallel lead programs in ROS1-positive and ALK-positive NSCLC.
• The Company expects to begin enrollment for the ALKAZAR Phase 3 trial early in the second half of 2025.
• The Company completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) and aligned on its plans to move forward with an NDA submission seeking an indication for the treatment of zidesamtinib for TKI pre-treated patients with locally advanced or metastatic ROS1-positive NSCLC.
• The Company plans to initiate a rolling NDA submission in July 2025 with completion targeted for the third quarter of 2025, and continues to engage with the FDA on potential opportunities for line-agnostic expansion.

Industry Context

This announcement positions Nuvalent as a significant player in targeted oncology, specifically for NSCLC with ROS1 and ALK mutations. The positive data for zidesamtinib, especially its efficacy in pre-treated patients and those with CNS metastases and resistance mutations, addresses critical unmet needs in these patient populations. The advancement of neladalkib into Phase 3 against a standard of care (alectinib) indicates a strong competitive stance in the ALK-positive NSCLC space. The FDA's RTOR program acceptance highlights the potential for accelerated market entry, reflecting the high medical need and promising nature of the data.

Comparison to Industry Standards

• The ORR of 44% for zidesamtinib in TKI pre-treated ROS1-positive NSCLC patients is competitive, especially considering the high proportion of patients with prior chemotherapy (53%), multiple prior TKIs (50%), and secondary resistance mutations (36%). For comparison, entrectinib showed an ORR of 39% in TKI-pretreated patients (STARTRK-2 trial), and lorlatinib showed an ORR of 36% in ROS1-positive NSCLC patients who had received prior crizotinib. Repotrectinib showed an ORR of 38% in ROS1 TKI-pretreated patients (TRIDENT-1 study).
• The intracranial ORR (IC-ORR) of 48% and 20% intracranial complete responses (CR) for zidesamtinib in patients with measurable CNS lesions is highly significant, as CNS metastases are a common challenge in NSCLC. For patients previously treated with crizotinib (a TKI with limited brain penetrance), the IC-ORR was 85% with 54% intracranial CRs, demonstrating strong brain penetration and efficacy. This compares favorably to other brain-penetrant TKIs like lorlatinib, which has shown high intracranial activity (e.g., 68% IC-ORR in ALK-positive NSCLC patients with CNS metastases).
• The emerging median duration of response (mDOR) of 22.0 months for zidesamtinib in TKI pre-treated patients is very promising, suggesting durable responses, which is a key differentiator in oncology treatments.
• The preliminary ORR of 89% in TKI-naive ROS1-positive NSCLC patients is exceptionally high and, if sustained, would be highly competitive with current front-line ROS1 TKIs like crizotinib (ORR ~72%) and entrectinib (ORR ~78%).
• The ALKAZAR Phase 3 trial design for neladalkib, comparing it against alectinib (a current front-line standard of care), indicates Nuvalent's confidence in neladalkib's potential to be a best-in-class ALK inhibitor. Alectinib itself demonstrated superior efficacy over crizotinib in the ALEX study (PFS HR 0.47).

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical data, potential for accelerated FDA approval, and advancement of pipeline, which could lead to increased share price and future revenue streams.
• Patients: Significant positive impact as zidesamtinib shows promise for a difficult-to-treat population (TKI pre-treated, CNS metastases, resistance mutations) and potentially a new front-line option. Neladalkib also offers a potential new treatment for ALK-positive NSCLC.
• Employees: Positive impact due to company progress, potential for growth, and successful R&D efforts.
• Healthcare Providers: Provides new, effective treatment options for NSCLC patients with specific mutations.
• Competitors: May face increased competition from Nuvalent's promising drug candidates.

Next Steps

• Initiate a rolling NDA submission for zidesamtinib in July 2025.
• Complete the rolling NDA submission for zidesamtinib in the third quarter of 2025.
• Continue engaging with the FDA on potential opportunities for line-agnostic expansion for zidesamtinib.
• Begin enrollment for the ALKAZAR Phase 3 trial for neladalkib early in the second half of 2025.
• Ongoing global enrollment for the Phase 2 TKI-naive cohort in the ARROS-1 clinical trial.

Key Dates

Recommendation

Keywords

Nuvalent, Zidesamtinib, Neladalkib, ROS1-positive NSCLC, ALK-positive NSCLC, Non-Small Cell Lung Cancer, TKI, Tyrosine Kinase Inhibitor, ARROS-1, ALKAZAR, Clinical Trial, Phase 1/2, Phase 3, FDA, NDA, Oncology, Drug Development, Biotechnology, Pharmaceutical, Cancer Treatment